Jaime Weimer - Profile and Journalist Details

Find journalists that align with your industry, location and vision. Unlock Jaime Weimer's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.

Get connected with journalists today
Jaime Weimer

Jaime Weimer

Verified

Host, The Oncology Nursing Podcast

Indianapolis

Journalist Type

Seniority Positions

Industries

-

Content

Total articles 4

  • Oncology Drug Reference Sheet: Pafolacianine

    By Jaime Weimer, Jaime Weimer MSN| Oncology Nursing Society@ An optical imaging agent shown to improve diagnostic accuracy, pafolacianine (Cytalux™) was approved on November 29, 2021, for use in adult patients with known or suspected ovarian cancer as adjunct therapy in conjunction with planned intraoperative identification of malignant lesions. Pafolacianine is used in combination with a near-infrared (NIR) fluorescence imaging system that requires specialized training provided by the device manufacturer.

    By Jaime Weimer, Jaime Weimer MSN · Oncology Nursing Society

    Aug. 15, 2024

  • Prevent Implicit Bias in Patient Care With These Cultural Conversation Starters

    By Jaime Weimer, Jaime Weimer MSN| Oncology Nursing Society@ Each clinical encounter with a patient brings together three different cultural perspectives: the patient’s, the nurse’s, and health care’s own culture. Patient-centered care acknowledges and responds to the unique needs and preferences of each patient in the context of their culture. As we approach our patients with respect, humility, and curiosity to learn more, we must ask questions to help prevent assumptions, generalizations, and implicit bias from influencing our interactions. Carrillo et al.

    By Jaime Weimer, Jaime Weimer MSN · Oncology Nursing Society

    Aug. 15, 2024

  • Oncology Drug Reference Sheet: Pafolacianine

    By Jaime Weimer, Jaime Weimer MSN| Oncology Nursing Society@ An optical imaging agent shown to improve diagnostic accuracy, pafolacianine (Cytalux™) was approved on November 29, 2021, for use in adult patients with known or suspected ovarian cancer as adjunct therapy in conjunction with planned intraoperative identification of malignant lesions. Pafolacianine is used in combination with a near-infrared (NIR) fluorescence imaging system that requires specialized training provided by the device manufacturer.

    By Jaime Weimer, Jaime Weimer MSN · Oncology Nursing Society

    Aug. 15, 2024

As seen in

Company Info

The Oncology Nursing Podcast